Urine Albumin/Creatinine Ratio: Longevity-Medicine Target Ranges Explained

The urine albumin/creatinine ratio (uACR, sometimes called the microalbumin/creatinine ratio or spot ACR) is a spot urine test that reports how much albumin is present relative to urinary creatinine, expressed in mg/g (or mg/mmol outside the US). It is distinct from a 24-hour urine protein collection, which measures total protein excretion over a full day, and from a standalone urine microalbumin concentration, which is not corrected for urine dilution. uACR is the test referenced throughout current chronic kidney disease (CKD) staging guidance.

The direct answer: Standard clinical guidance, most recently the KDIGO 2024 CKD guideline, classifies uACR below 30 mg/g as normal to mildly increased (category A1), 30 to 300 mg/g as moderately increased (A2), and above 300 mg/g as severely increased (A3). Some longevity-medicine practices use a stricter internal target of under 10 mg/g because several cardiovascular cohort studies report that risk begins climbing within the A1 range itself, not only after crossing 30 mg/g. That sub-30 gradient is a real and reproducible epidemiologic pattern, but a specific "10 mg/g" cutoff is a clinical judgment extrapolated from population risk curves, not a guideline-endorsed diagnostic threshold, and individual dosing or treatment decisions should not be made from a single number without a clinician's review.

At a glance

• Standard normal range / below 30 mg/g (KDIGO A1 category)
• Moderately increased / 30 to 300 mg/g (A2, historically called microalbuminuria)
• Severely increased / above 300 mg/g (A3, historically called macroalbuminuria)
• Longevity-practice target used by some clinics / below 10 mg/g, based on epidemiologic risk gradients, not a formal guideline cutoff
• Preferred specimen / first-morning spot urine, single void
• Screening interval / annually for diabetes, hypertension, obesity, or metabolic syndrome, per general guideline practice
• Common confounders / vigorous exercise, fever, urinary tract infection, menstruation, dehydration
• Confirmation rule / repeat an elevated result before treating; guidelines generally call for confirmation on more than one sample over weeks to months
• Evidence status / A1/A2/A3 staging is guideline-established; the sub-30 mg/g risk gradient is supported by observational cohorts; a fixed "optimal" number below 10 mg/g is not an established guideline target

What the test actually measures

Healthy glomeruli retain albumin almost completely. When the filtration barrier is stressed, whether by high glucose, high blood pressure, or inflammation, albumin leaks across and appears in urine in small quantities long before overt kidney disease is apparent. Because urine concentration varies with hydration, a raw albumin number is hard to interpret on its own. Dividing by creatinine corrects for that dilution effect, which is why a single spot sample can substitute for a cumbersome 24-hour collection in most clinical situations. First-morning urine is generally preferred because it avoids orthostatic proteinuria, a benign pattern where albumin appears only after prolonged upright posture and clears by morning.

Day-to-day biological variability in uACR is meaningful; a person's result can shift substantially between two mornings without any change in true kidney health. This is why a single elevated reading should not be treated as a diagnosis. It should be repeated after ruling out transient causes such as recent vigorous exercise, fever, active urinary tract infection, acute illness, or, in women, menstrual contamination.

Standard clinical categories (KDIGO 2024)

KDIGO (Kidney Disease: Improving Global Outcomes) assigns three albuminuria categories that combine with eGFR-based categories to produce an overall CKD risk grid, current as of the 2024 guideline update.

A person with a reassuring eGFR but a uACR in the A2 or A3 range is generally classified at higher overall risk than the eGFR number alone would suggest. This is a core reason albuminuria testing is recommended alongside, not instead of, eGFR.

Is "normal" (below 30 mg/g) actually risk-free?

Not entirely, and this is the crux of the longevity-medicine argument. Multiple prospective cohort studies of general and diabetic populations have reported that cardiovascular and all-cause mortality rise in a graded fashion as uACR increases within the A1 category itself, with the gradient often becoming visible somewhere in the high single digits to low double digits of mg/g, well before the 30 mg/g threshold. The magnitude of that risk increase varies across studies and populations, and exact hazard ratios attributed to specific cutoffs in earlier drafts of this material could not be locally verified against a primary source; readers should treat any specific multiplier (for example, "a 20% increase in risk above 10 mg/g") as requiring confirmation in the primary literature before being repeated as fact. What is reasonably well supported is the directional finding: within the conventional normal range, higher is still associated with more cardiovascular and kidney risk than lower.

The longevity-medicine target of under 10 mg/g: what it is and is not

Some longevity and preventive-medicine practices, including the framework below, use a target of under 10 mg/g rather than the guideline's under 30 mg/g. The rationale is the risk-gradient pattern described above: if cardiovascular risk starts separating within the A1 range, then optimizing toward the lower end of that range plausibly matters even for people who will never be diagnosed with CKD by conventional criteria.

This is best understood as site judgment built on an epidemiologic pattern, not a guideline recommendation and not an FDA-regulated diagnostic cutoff. No major guideline body currently endorses "10 mg/g" as a treatment trigger. A uACR of 15 mg/g in an otherwise low-risk person is not, by itself, an indication to start medication; it is a reasonable prompt to look at blood pressure, glucose, weight, and sleep, and to recheck the trend over time. Readers whose result sits between 10 and 29 mg/g should discuss the finding with a clinician who can weigh it alongside their full risk profile rather than treating the number in isolation.

What tends to push uACR upward

Diabetes and insulin resistance. Diabetic kidney disease is the leading cause of elevated albuminuria worldwide, and both the ADA and KDIGO recommend annual uACR screening for adults with type 2 diabetes from diagnosis, and for adults with type 1 diabetes generally starting around five years after diagnosis. Insulin resistance without a formal diabetes diagnosis has also been associated with modestly higher uACR in population survey data, though exact numeric differences vary by dataset and should be confirmed against the specific source before being quoted precisely.

Hypertension. Elevated blood pressure stretches the glomerular capillary wall and is one of the two dominant drivers of albuminuria globally, alongside diabetes. Blood pressure-lowering trials in hypertensive kidney disease populations have generally shown that reducing blood pressure reduces uACR, though the size of the effect depends on the population and baseline pressure.

Obesity and visceral adiposity. Cross-sectional studies have linked higher BMI and waist circumference to higher odds of elevated uACR, plausibly through adipose-driven inflammation and altered glomerular hemodynamics, independent of diabetes and hypertension.

Obstructive sleep apnea. Intermittent hypoxia activates the renin-angiotensin-aldosterone system overnight, and observational studies have associated moderate-to-severe OSA with higher rates of albuminuria compared with people without OSA. Whether treating OSA meaningfully lowers uACR is plausible but should be considered an area with limited and mixed direct trial evidence rather than an established fact.

Interventions with trial evidence behind them

RAAS blockade (ACE inhibitors and ARBs). These reduce intraglomerular pressure and lower uACR by a mechanism partly independent of their blood pressure effect. They are first-line therapy once albuminuria is confirmed in the setting of diabetes or hypertension. ACE inhibitors and ARBs should not generally be combined (dual RAAS blockade), a conclusion supported by large cardiovascular outcome trials showing increased adverse events without added kidney benefit from combination therapy.

SGLT2 inhibitors. Dedicated kidney-outcome trials, including CREDENCE and DAPA-CKD, established that this drug class reduces albuminuria and slows progression of CKD in people with type 2 diabetes and, in DAPA-CKD, in people without diabetes as well. These trials are foundational to current guideline recommendations favoring SGLT2 inhibitors in CKD with meaningfully elevated albuminuria. Exact percentage reductions vary by trial and subgroup; readers who need a precise figure for a specific population should verify it directly against the published trial report rather than a secondhand summary.

GLP-1 receptor agonists. The FLOW trial, published in 2024, was the first dedicated kidney-outcomes trial for a GLP-1 receptor agonist (semaglutide) in type 2 diabetes with CKD, and it reported benefit on a composite kidney endpoint. This is a meaningful and relatively recent addition to the treatment landscape; the magnitude of the albuminuria-specific effect should be checked against the primary publication before being cited with a specific percentage.

Blood pressure and sodium intake. Intensive blood pressure control and dietary sodium restriction (generally under about 2,300 mg/day) are both associated with lower uACR and appear to potentiate the effect of RAAS blockade. These are reasonable first steps for anyone with a borderline result, independent of whether medication is eventually needed.

How the test is actually done

1. First-morning void is preferred; avoid vigorous exercise in the prior 24 hours.
2. Standard mid-stream clean-catch collection into a sterile container.
3. Refrigerate if the sample will not be processed within about two hours.
4. The lab reports albumin and creatinine separately and calculates the ratio, in mg/g in the US or mg/mmol elsewhere (multiply mg/mmol by roughly 8.8 to approximate mg/g).

Retesting. An elevated result under either the guideline threshold (above 30 mg/g) or a stricter longevity target (above 10 mg/g) generally warrants a repeat test rather than immediate treatment, especially if a plausible transient cause (illness, exercise, infection, menstruation) was present. Guideline practice generally favors confirming persistent albuminuria across more than one sample collected over weeks to months before treating it as a diagnosis; the exact protocol (for example, "two of three samples over three months") should be confirmed with the specific guideline document in use rather than assumed universal.

Populations where interpretation shifts

Women and hormonal status. Estrogen appears to have some protective effect on the glomerular filtration barrier, and uACR tends to be somewhat lower in premenopausal women than in age-matched men, with a possible modest rise after menopause in observational data. This pattern is not a treatment indication for hormone therapy; it is a reason to interpret a postmenopausal woman's uACR trend in context rather than isolation.

Men on testosterone therapy. Physiologic testosterone replacement in hypogonadal men does not appear, in available observational data, to independently worsen uACR, though monitoring remains reasonable in men who also carry metabolic risk factors.

Older adults and kidney aging. Glomerular changes are a normal part of aging, and eGFR gradually declines with age even in people without diagnosed CKD. uACR also tends to run somewhat higher in older adults without disease than in younger adults. Current guidelines do not formally age-adjust the uACR thresholds, which means a clinician reading a modestly elevated result in a person in their seventies should weigh it differently than the same number in someone in their thirties, using clinical judgment rather than a separate published age-adjusted cutoff.

A 2025 study using combined eGFR-ACR risk stratification examined rapid kidney function decline across different aging phenotypes in older Chinese adults (PubMed). This kind of combined-marker approach, using eGFR and ACR together rather than either alone, is a reasonable direction for refining risk prediction in older populations, but the study's population (older adults in China) limits how directly its specific risk estimates transfer to younger adults, other ethnic populations, or the "longevity medicine" population typically screened well before any decline in kidney function is apparent. It should be read as supporting the general principle of combined-marker risk stratification, not as a source for a specific numeric target applicable to all readers.

Evidence boundary: what is established, what is not

Established, guideline-level: the A1/A2/A3 category definitions; annual uACR screening for adults with diabetes and generally recommended for hypertension or metabolic syndrome; RAAS blockade and SGLT2 inhibitors as guideline-recommended therapy once albuminuria and CKD are confirmed; the practice of using eGFR and uACR together rather than either alone.

Plausible but not fully settled: a specific numeric "optimal" uACR target below the guideline's normal threshold; the precise size of cardiovascular risk increase at any given uACR level within the normal range; whether treating OSA or optimizing sleep meaningfully lowers uACR independent of weight and blood pressure changes; whether GLP-1 receptor agonist benefits on albuminuria are additive to, or overlapping with, SGLT2 inhibitor benefits in the same patient.

Not established: a validated, guideline-endorsed "longevity" cutoff of 10 mg/g as a treatment trigger; age-adjusted normal ranges as formal guideline policy; that any single uACR value, absent trend data and clinical context, should drive a medication decision on its own.

A reader decision framework: what to actually do with your result

This is a working framework, not a guideline, meant to help a reader decide their next step rather than fixate on one number.

Exceptions that change the read: an isolated elevated result during a febrile illness, within 24 hours of hard exercise, during a urinary tract infection, or during menstruation is not reliable and should simply be repeated once the transient factor resolves rather than acted on. A result should also be interpreted alongside eGFR; a uACR in the A2 range with a falling eGFR trend is a stronger signal than the same uACR with a stable eGFR over several years.

When urgent care is appropriate: a new uACR above 300 mg/g together with swelling, marked reduction in urine output, or a rapidly rising eGFR-based decline in kidney function is not a routine annual-screening finding and warrants prompt medical evaluation rather than a scheduled recheck in a few months.

How uACR fits with other labs

uACR is most informative alongside eGFR, since KDIGO's risk grid explicitly combines the two. It is also commonly reviewed alongside HbA1c or fasting glucose (to see whether rising albuminuria tracks glycemic control), blood pressure trends, and body weight. None of these companion values changes what the uACR number itself means, but they help a clinician judge whether an elevated result reflects an active, modifiable process or an isolated finding.

Common questions

Is a uACR of 25 mg/g something to worry about? It falls within the KDIGO "normal" A1 category, so it does not meet the guideline definition of albuminuria. Some longevity-oriented clinicians would still flag it as worth tracking and addressing modifiable risk factors, given cohort data suggesting a risk gradient within the normal range, but it is not, by itself, a treatment indication.

Does a normal uACR guarantee healthy kidneys? No test does that in isolation. uACR is paired with eGFR precisely because either marker alone can miss important information; a normal uACR with a declining eGFR trend, or vice versa, both warrant follow-up.

Can lifestyle changes lower uACR without medication? Weight loss, blood pressure control, reduced dietary sodium, and improved glycemic control are all reasonably supported ways to lower uACR in early, mild elevations. Once albuminuria is confirmed in the guideline-defined A2 or A3 range with diabetes or hypertension present, medication (typically RAAS blockade, often with an SGLT2 inhibitor) becomes standard practice rather than an optional add-on.

How often should uACR be tested? Annually is standard practice for adults with diabetes, hypertension, obesity, or a family history of kidney disease. More frequent rechecking (every few months) is reasonable when a result is borderline or newly elevated, mainly to see whether it is a stable trait or a rising trend.

References

• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024 update; consult the current KDIGO publication directly for the full A1/A2/A3 staging tables and referral thresholds).
• American Diabetes Association Standards of Care in Diabetes (2024 edition; consult current ADA guidance directly for the specific albuminuria screening schedule).
• CREDENCE, DAPA-CKD, and FLOW are named, publicly reported kidney-outcome trials referenced above by name; readers who need exact effect sizes should consult the original trial publications rather than this summary.
• eGFR-ACR risk stratification of rapid kidney function decline across aging phenotypes in older Chinese adults (2025): https://pubmed.ncbi.nlm.nih.gov/41293479/

This article synthesizes general guideline and cohort-level evidence for educational purposes. It does not provide individualized diagnosis, dosing, or treatment recommendations. Anyone with an abnormal uACR result should discuss it with a qualified clinician who can review it alongside eGFR, medical history, and other relevant labs.